Stock Events

Stock Events

Arrowhead Pharmaceuticals 

€60.28
89
+€0.68+1.14% Today

Statistics

Day High
59.82
Day Low
59.12
52W High
63.28
52W Low
11.48
Volume
0
Avg. Volume
-
Mkt Cap
8.44B
P/E Ratio
46.19
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-1.39
-0.01
1.37
2.75
Expected EPS
-1.166855
Actual EPS
N/A

Financials

0.34%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
1.45BRevenue
4.88MNet Income

Analyst Ratings

69.9Average Price Target
The highest estimate is 83.47.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
88%
Hold
13%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HDP1.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alnylam Pharmaceuticals
ALNY
Mkt Cap40.77B
Alnylam Pharmaceuticals is a direct competitor in the RNA interference (RNAi) therapeutic space, targeting similar diseases as Arrowhead.
Ionis Pharmaceuticals
IONS
Mkt Cap12.1B
Ionis Pharmaceuticals competes in the development of RNA-targeted therapies, sharing a focus on genetic and rare diseases.
Moderna
MRNA
Mkt Cap20.12B
Moderna is involved in mRNA therapeutics and vaccines, representing competition in the broader RNA-based treatment market.
BioNTech
BNTX
Mkt Cap26.67B
BioNTech competes in the mRNA space, particularly in vaccines, but its technology could extend into therapeutic areas overlapping with Arrowhead's interests.
Sarepta Therapeutics
SRPT
Mkt Cap2.13B
Sarepta Therapeutics focuses on RNA-targeted treatments, especially for rare diseases, competing in the genetic medicine field alongside Arrowhead.
Arcturus Therapeutics
ARCT
Mkt Cap244.15M
Arcturus Therapeutics works on mRNA medicines for various diseases, including those in Arrowhead's target areas, making them competitors in RNA-based therapies.
CRISPR Therapeutics
CRSP
Mkt Cap4.7B
CRISPR Therapeutics is focused on gene editing, a different but related approach to treating diseases at the genetic level, potentially competing for similar therapeutic indications.
Intellia Therapeutics
NTLA
Mkt Cap1.61B
Intellia Therapeutics is another company working on CRISPR-based gene editing, competing in the genetic medicine space where RNA therapies like Arrowhead's are also relevant.

About

There is no Profile data available for HDP1.MU.
Show more...
CEO
Dr. Christopher R. Anzalone Ph.D.
Employees
711
Country
United States
ISIN
US04280A1007
WKN
000A2AGYB

Listings

MU
DE
HDP1.MU
SA
BR
A2RR34.SA
STU
DE
HDP1.STU
MX
MX
ARWR.MX

0 Comments

Share your thoughts

FAQ

What is Arrowhead Pharmaceuticals stock price today?▼
The current price of HDP1.F is €60.28 EUR — it has increased by +1.14% in the past 24 hours. Watch Arrowhead Pharmaceuticals stock price performance more closely on the chart.
What is Arrowhead Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Arrowhead Pharmaceuticals stocks are traded under the ticker HDP1.F.
Is Arrowhead Pharmaceuticals stock price growing?▼
HDP1.F stock has fallen by -4.47% compared to the previous week, the month change is a +19.9% rise, over the last year Arrowhead Pharmaceuticals has showed a +407.81% increase.
What is Arrowhead Pharmaceuticals market cap?▼
Today Arrowhead Pharmaceuticals has the market capitalization of 8.44B
When is the next Arrowhead Pharmaceuticals earnings date?▼
Arrowhead Pharmaceuticals is going to release the next earnings report on May 07, 2026.
What were Arrowhead Pharmaceuticals earnings last quarter?▼
HDP1.F earnings for the last quarter are 0.19 EUR per share, whereas the estimation was 0.03 EUR resulting in a +491.83% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Arrowhead Pharmaceuticals revenue for the last year?▼
Arrowhead Pharmaceuticals revenue for the last year amounts to 1.45B EUR.
What is Arrowhead Pharmaceuticals net income for the last year?▼
HDP1.F net income for the last year is 4.88M EUR.
How many employees does Arrowhead Pharmaceuticals have?▼
As of April 29, 2026, the company has 711 employees.
In which sector is Arrowhead Pharmaceuticals located?▼
Arrowhead Pharmaceuticals operates in the Health & Wellness sector.
When did Arrowhead Pharmaceuticals complete a stock split?▼
The last stock split for Arrowhead Pharmaceuticals was on November 18, 2011 with a ratio of 1:10.
Where is Arrowhead Pharmaceuticals headquartered?▼
Arrowhead Pharmaceuticals is headquartered in Pasadena, United States.